Mesoblast Limited Quick Ratio (MESO) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Mesoblast Limited  (NASDAQ: MESO)

Mesoblast Limited's Quick Ratio

MESO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Mesoblast Limited's Cash & cash equivalent, this led to improvement in Mesoblast Limited's Quick Ratio to 1.9, above Mesoblast Limited average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 112 other companies have achieved higher Quick Ratio than Mesoblast Limited in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 1629, from total ranking in the third quarter 2025 at 2576.

Explain Quick Ratio?
How much Cash & cash equivalents MESO´s has?
What are MESO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MESO Quick Ratio (Jun 30 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Jun 30 2024)
Q4
Y / Y Current Liabilities Change 20.25 % -29.48 % 103.01 % -29.48 % 106.84 %
Y / Y Cash & cash equivalent Change 241.78 % 156.59 % -11.72 % 156.59 % -50.96 %
Quick Ratio MRQ 1.9 1.57 0.95 1.57 0.67
MESO's Total Ranking # 1629 # 2576 # # #
Seq. Current Liabilities Change -33.29 % 55.56 % -35.72 % 80.26 % -60.88 %
Seq. Cash & cash equivalent Change -19.55 % 156.59 % -61.03 % 324.81 % -39.6 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 113
Healthcare Sector # 563
Overall Market # 1629


Quick Ratio Statistics
High Average Low
2.82 1.28 0.43
(Jun 30 2023)   0




Financial Statements
Mesoblast Limited's Current Liabilities $ 68 Millions Visit MESO's Balance sheet
Mesoblast Limited's Cash & cash equivalent $ 130 Millions Visit MESO's Balance sheet
Source of MESO's Sales Visit MESO's Sales by Geography


Cumulative Mesoblast Limited's Quick Ratio

MESO's Quick Ratio for the trailling 12 Months

MESO Quick Ratio

 (Jun 30 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -10.72 % -6.53 % 17.89 % 2.84 % 68.84 %
Y / Y Cash & cash equivalent TTM Growth 119.34 % 54.33 % 14.96 % 22.62 % -20.2 %
Quick Ratio TTM 1.52 1.29 0.88 0.99 0.62
Total Ranking TTM # 3287 # 3622 # # #
Seq. Current Liabilities TTM Growth 3.51 % -11.56 % 9.92 % -11.27 % 8.38 %
Seq. Cash & cash equivalent TTM Growth 21.68 % 30.29 % -2.5 % 41.91 % -14.38 %

Quick ratio ranking by company, industry and sector >> Back to MESO Financial Strength Comparisons >> Go to Compare MESO Quick Ratio to its Competitors

On the trailing twelve months basis MESO Cash & cash equivalent more than doubled by 241.78 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Mesoblast Limited's Quick Ratio to 1.52, above MESO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 147 other companies have achieved higher Quick Ratio than Mesoblast Limited. While Quick Ratio overall ranking has improved so far to 3287, from total ranking during the twelve months ending third quarter 2025 at 3622.

Explain Quick Ratio?
How much Cash & cash equivalents MESO´s has?
What are MESO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 148
Healthcare Sector # 871
Within the Market # 3287


trailing twelve months Quick Ratio Statistics
High Average Low
1.21 0.85 0.37
(Jun 30 2022)   0




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Atyr Pharma Inc   5.17 $ 80.346  Millions$ 15.531  Millions
Inhibrx Biosciences Inc   5.07 $ 186.567  Millions$ 36.770  Millions
Vaxcyte Inc   4.82 $ 306.744  Millions$ 63.628  Millions
Cabaletta Bio Inc   4.69 $ 194.682  Millions$ 41.540  Millions
Agomab Therapeutics Nv  4.65 $ 96.788  Millions$ 20.820  Millions
Precision Biosciences Inc  4.59 $ 62.242  Millions$ 13.568  Millions
Cardiff Oncology Inc   4.45 $ 70.957  Millions$ 15.948  Millions
Fennec Pharmaceuticals Inc   4.45 $ 37.410  Millions$ 8.414  Millions
Vivosim Labs Inc   4.23 $ 9.055  Millions$ 2.142  Millions
Lineage Cell Therapeutics Inc   3.93 $ 42.288  Millions$ 10.756  Millions
Inmune Bio Inc   3.89 $ 33.374  Millions$ 8.586  Millions
Cardiol Therapeutics inc   3.79 $ 16.405  Millions$ 4.332  Millions
Arcellx Inc   3.72 $ 453.103  Millions$ 121.850  Millions
Alector Inc   3.64 $ 307.280  Millions$ 84.354  Millions
Lenz Therapeutics Inc   3.62 $ 37.608  Millions$ 10.398  Millions
Biontech Se  3.61 $ 8,655.360  Millions$ 2,399.376  Millions
Relay Therapeutics Inc   3.50 $ 113.941  Millions$ 32.525  Millions
Vor Biopharma Inc   3.41 $ 200.565  Millions$ 58.773  Millions
Kodiak Sciences Inc   3.36 $ 104.165  Millions$ 31.011  Millions
Moderna Inc   3.26 $ 5,131.000  Millions$ 1,572.000  Millions
Recursion Pharmaceuticals Inc   3.20 $ 525.110  Millions$ 164.026  Millions
Turnstone Biologics Corp   3.13 $ 18.594  Millions$ 5.934  Millions
Immunitybio inc   3.03 $ 153.658  Millions$ 50.644  Millions
Passage Bio Inc   2.91 $ 57.626  Millions$ 19.801  Millions
Prime Medicine Inc   2.88 $ 98.343  Millions$ 34.109  Millions
Twist Bioscience Corporation  2.88 $ 250.798  Millions$ 87.070  Millions
Vericel Corporation  2.84 $ 116.881  Millions$ 41.132  Millions
Sutro Biopharma Inc   2.76 $ 205.131  Millions$ 74.246  Millions
X4 Pharmaceuticals Inc  2.75 $ 62.951  Millions$ 22.896  Millions
Editas Medicine Inc   2.71 $ 178.501  Millions$ 65.937  Millions

Date modified: 2026-07-07T12:24:10+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.